Table 4.
Univariate analysis of prognostic factors for persistent/recurrent disease or disease-related death in patients with multifocal PTC.
| Excellent response n = 120 (%) | Indeterminate response n = 21 (%) | BPD + SPD + TCD n = 11 (%) | p value | |
|---|---|---|---|---|
| Age at diagnosis (mean ± SD) | 48 years ± 14 | 47 years ± 15 | 46 years ± 23 | NS |
| Gender | NS | |||
| Male | 33 (27.5%) | 4 (19%) | 5 (45.5%) | |
| Female | 87 (72.5%) | 17 (81%) | 6 (54.5%) | |
| PTC histological classification | NS | |||
| Classical variant | 81 (67.5%) | 15 (71.4%) | 6 (54.5%) | |
| Follicular variant | 7 (5.8%) | 1 (4.8%) | 1 (9.1%) | |
| Oxyphilic variant | 9 (7.5%) | 1 (4.8%) | 1 (9.1%) | |
| Aggressive variants | 23 (19.2%) | 4 (19%) | 3 (27.3%) | |
| PTS [median; (IQR)] | 13 mm (9–20) | 12 mm (10.5–15) | 25 mm (16.25–41.5) | 0.004 |
| Primary tumor size | NS | |||
| ⩽10 mm (microPTC) | 39 (32.5%) | 5 (23.8%) | 0 | |
| >10 mm | 81 (67.5%) | 16 (76.2%) | 11 (100%) | |
| TNF [median; (IQR)] | 2 (2–4) | 3 (2–6.25) | 3 (2–3) | NS |
| SDSF [median; (IQR)] | 21 mm (14–30) | 23 mm (15.5–32.75) | 62 mm (24–67.5) | 0.004 |
| Vascular invasion | 46 (61.3%) | 15 (83.3%) | 7 (100%) | 0.03 |
| Cervical lymph node involvement | 51 (45.9%) | 13 (68.4%) | 8 (80%) | 0.03 |
| Cervical lymph node involvement | 0.001 | |||
| Central, N1a | 33 (29.7%) | 8 (42.1%) | 1 (10%) | |
| Lateral, N1b | 18 (16.2%) | 5 (26.3%) | 7 (70%) | |
| Distant metastases | 0 | 0 | 2 (18.2%) | <0.0001 |
| Bilaterality | 86 (71.7%) | 15 (71.4%) | 10 (90.9%) | NS |
| TNM stage (8th edition) | 0.03 | |||
| Stage I | 105 (87.5%) | 19 (90.5%) | 6 (54.5%) | |
| Stage II | 14 (11.7%) | 2 (9.5%) | 5 (45.5%) | |
| Stage III | 1 (0.8%) | 0 | 0 | |
| Stage IV | 0 | 0 | 0 | |
| T-categories based on PTS (TNM, 8th edition) | 0.004 | |||
| T1a | 37 (30.8%) | 5 (23.8%) | 0 | |
| T1b | 53 (44.5%) | 14 (66.7%) | 4 (36.4%) | |
| T2 | 17 (14.2%) | 1 (4.8%) | 2 (18.2%) | |
| T3a | 7 (5.8%) | 1 (4.8%) | 3 (27.3%) | |
| T3b | 4 (3.3%) | 0 | 0 | |
| T4a | 2 (1.7%) | 0 | 2 (18.2%) | |
| T4b | 0 | 0 | 0 | |
| T-categories based on SDSF (TNM, 8th edition) | 0.0003 | |||
| T1a | 12 (10%) | 2 (9.5%) | 0 | |
| T1b | 42 (35%) | 7 (33.3%) | 1 (9.1%) | |
| T2 | 48 (40%) | 10 (47.6%) | 2 (18.2%) | |
| T3a | 12 (10%) | 2 (9.5%) | 6 (54.5%) | |
| T3b | 4 (3.3%) | 0 | 0 | |
| T4a | 2 (1.7%) | 0 | 2 (18.2%) | |
| T4b | 0 | 0 | 0 | |
| Postoperative RAI therapy | 109 (91.6%) | 19 (90.5%) | 10 (90.9%) | NS |
| Administered activity of RAI [median; (IQR)] | 100 mCi (70–150) | 125 mCi (50–150) | 150 mCi (150–150) | 0.03 |
| Follow-up period (mean ± DS) | 69 months ± 30 | 68 months ± 31 | 46 months ± 40 | NS |
| Second treatment | 6 (5%) | 8 (38.1%) | 8 (72.7%) | <0.0001 |
| BRAF mutation (FNAC) | 78 (65.5%) | 13 (61.9%) | 9 (81.8%) | NS |
| TERT promoter mutation (FNAC) | 4 (3.3%) | 0 | 2 (18.2%) | 0.03 |
| Initial risk stratification system scores | 0.0003 | |||
| Low | 37 (31.1%) | 2 (9.5%) | 2 (18.2%) | |
| Intermediate | 78 (65.5%) | 16 (76.2%) | 5 (45.5%) | |
| High | 4 (3.4%) | 3 (14.3%) | 4 (36.4%) |
BPD, biochemical persistent disease; FNAC, fine needle aspiration cytology; IQR, interquartile range; NS, not significant; PTS, primary tumor size; RAI, radioactive immunotherapy; SDSF, sum of diameters of single foci; SPD, structural persistent disease; TCD, death due to thyroid cancer; TNF, total number of foci.